| Authors: |
Beksac M; Department of Hematology, Ankara University, Ankara, Turkey. Electronic address: mbeksac56@gmail.com., Spicka I; 1st Department of Medicine - Department of Hematology, First Faculty of Medicine Charles University and General Hospital in Prague, Prague, Czech Republic., Hajek R; Department of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Bringhen S; SSD Clinical trial in onco-ematologia e myeloma multiplo, Division of Hematology, AOU Città della salute e della scienza di Torino, Torino, Italy., Jelínek T; Department of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Martin T; Department of Hematology, University of California at San Francisco, San Francisco, CA, USA., Mikala G; National Institute for Hematology and Infectious Diseases, Department of Hematology and Stem Cell Transplantation, South Pest Central Hospital, Budapest, Hungary., Moreau P; Hematology Department, Nantes University Hospital, Nantes, France., Symeonidis A; Hematology Division, Department of Internal Medicine, University of Patras Medical School, Patras, Greece., Rawlings AM; Sanofi, Cambridge, MA, USA., van de Velde H; Sanofi, Cambridge, MA, USA., Richardson PG; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. |
